Advanced practice providers – an evolving pulmonary medicine role

BY CHRISTINE KILGORE
MDedge News

The integration of advanced practice providers (APPs) into pulmonology practice is in flux and deepening across numerous settings, from outpatient clinics to intensive care and inpatient pulmonary consult services – and as it evolves, so do training issues.

Some institutions are developing pulmonary fellowship programs for APPs. This is a good indication that team-based pulmonology may be moving toward a time in the future when nurse practitioners (NPs) and physician assistants (PAs) join pulmonologists in practice after having undergone formal education in the subspecialty, rather than learning solely on the job from dedicated mentors.

Neither NPs nor PAs, who compose almost all of the APP workforce in pulmonology, currently have a pulmonary tract for training. “Weight falls on the employer’s shoulders to train and educate their APPs,” said Corinne R. Young, MSN, FNP-C, FCCP, director of APP and clinical services at Colorado Springs Pulmonary Consultants and founder and president of the Association of Pulmonary Advanced Practice Providers (APAPP), which launched in 2018.

OSA overlap impairs functional performance in COPD

BY HEIDI SPLETE
MDedge News

Obstructive sleep apnea (OSA) was associated with both impaired functional performance during exercise and overall worse outcomes in patients with chronic obstructive pulmonary disease (COPD), based on data from 34 adults.

Individuals with COPD are at increased risk for hospital readmissions and disease exacerbations, Patricia Faria Camargo, PhD, of Federal University of São Carlos (Brazil), and colleagues wrote. These patients often have concomitant OSA, which itself can promote adverse cardiovascular events, but the impact of the overlap of these two conditions on clinical outcomes has not been explored.

In a study published in Heart & Lung (2022 Oct 28. doi: 10.1016/j.hrtlng.2022.10.007), the researchers recruited 17 adults with COPD only and 17 with OSA and COPD. At baseline, patients underwent pulmonary function tests, PRSRT STD U.S. POSTAGE PAID HARRISBURG PA PERMIT 500 CHEST Physician 10255 W Higgins Road, Suite 280 Rosemont, IL 60018 CHANGE SERVICE REQUESTED
RSV MAY RAISE THE STAKES FOR OLDER ADULTS

Respiratory syncytial virus (RSV) is a common and contagious virus that typically produces mild, cold-like symptoms but can put older adults at risk for severe outcomes.1,2, *

Each year in the US, approximately 177,000 older adults are hospitalized and an estimated 14,000 of them die due to RSV infection.2

Those at high risk for severe illness from RSV include2,3:

- Older adults, especially those aged 65 and older
- Adults with chronic lung or heart disease
- Adults with weakened immune systems

RSV may exacerbate serious conditions such as4:

- Asthma
- Chronic obstructive pulmonary disease
- Congestive heart failure

Infection with RSV may put some older adults and adults with certain chronic medical conditions at increased risk.2,3

CDC=Centers for Disease Control and Prevention; CHF=congestive heart failure; COPD=chronic obstructive pulmonary disease.

Learn about the risks of RSV at RSVinAdults.com
RSV MAY RAISE THE STAKES FOR OLDER ADULTS

Respiratory syncytial virus (RSV) is a common and contagious virus that typically produces mild, cold-like symptoms but can put older adults at risk for severe outcomes. Each year in the US, approximately 177,000 older adults are hospitalized and an estimated 14,000 of them die due to RSV infection. Those at high risk for severe illness from RSV include:

- CDC=Centers for Disease Control and Prevention
- CHF=congestive heart failure
- COPD=chronic obstructive pulmonary disease

*The CDC states that adults at highest risk for severe RSV infection include older adults, especially those 65 years and older, adults with chronic heart or lung disease, and adults with weakened immune systems. Data are limited in assessing the risk of severe outcomes due to RSV infection in adults 60-64 years of age.*

References:
Providers // continued from page 1

knowledge, and motivation – but by “how much work a practice puts into [education and training],” she said.

An estimated 3,000-8,000 APPs are working in pulmonology, according to an analysis done by a marketing agency that has worked for the American College of Chest Physicians, Ms. Young said. A 2021 APAPP survey of its several hundred members at the time showed them working in hospital systems (41%), private practice (28%), university systems (10%), and other health care systems (21%). They indicated practicing in pulmonary medicine, sleep medicine, or critical care – or some combination of these areas – and the vast majority (82%) were seeing both new and established patients in their roles.

"Nobody knows exactly how many of us are out there,” Ms. Young said. “But CHEST and APAPP are making great efforts to be beacons to APPs working in this realm and to bring them together to have a voice.”

The APAPP wants to “close the education gap” and to “eventually develop a certification program to vet our knowledge in this area,” she said. “Right now, the closest we can get to vetting our knowledge is to become an FCCP through CHEST.”

Earning trust, seeking training

Omar Hussain, DO, has been practicing with an NP for over a decade in his role as an intensivist and knows what it’s like to train, supervise, and grow together. He and his private practice colleagues have a contract with Advocate Condell Hospital in Libertyville, Ill., to cover its ICU, and they hired their NP primarily, and non-critically ill patients in the ICU (for example, patients receiving postoperative monitoring).

The NP has been invaluable. “We literally sit next to each other and in the mornings we make a game plan of which patients she will tackle first and which ones I'll see first,” Dr. Hussain said. "When we're called by the nurse for an ICU evaluation [on the floor], we'll decide in real time how to intubate. It was a thoughtful and deliberate process, and "we used the same kind of mindset we've used when we've supervised residents at other institutions,” he said.

Dr. Hussain and his partners have been fortunate in having such a long-term relationship with an APP. Their NP had worked as a nurse in the ICU before training as an adult gerontology--acute care NP and joining Dr. Hussain’s practice, so she was also "well known to us.”

Rachel Adney, CPNP-PC, a certified pediatric NP in the division of pediatric pulmonology at Stanford (Calif.) Medicine Children’s Health, is an APP who actively sought advanced training. She joined Stanford in 2011 to provide ambulatory care, primarily, and having years of prior experience in asthma management and education, she fast became known as “the asthma person.”

After a physician colleague one day objected to her caring for a patient without asthma, Ms. Adney, the first APP in the division, approached John D. Mark, MD, program director of the pediatric fellowship program at Stanford, and inquired about training. "So I could have more breadth and depth across the whole pulmonary milieu." Together they designed a “mini pediatric pulmonary fellowship” for Ms. Adney, incorporating elements of the first year of Stanford's pediatric fellowship program as

“Nobody knows exactly how many of us are out there. But CHEST and APAPP are making great efforts to be beacons to APPs working in this realm and to bring them together to have a voice.”

Ms. Adney

...continued on following page
It's clear that "things are changing around the country" with increasing institutional interest in developing formal APP fellowship programs. Ms. Adney's curriculum consisted of 1,000 total hours of training, including 125 hours of didactic learning and 400 hours of inpatient and outpatient clinical training in areas such as cystic fibrosis, sleep medicine, bronchopulmonary dysplasia (BPD), neuromuscular disorders, and general pulmonary medicine. "Rachel rotated through clinics, first as an observer, then as a trainee ... and she attended lectures that my fellows attended," said Dr. Mark, who has long been a preceptor for APPs. "She became like a 1-year fellow in my division."

Today, Ms. Adney sees patients independently in four outreach clinics along California's central coast. "She sees very complicated pediatric pulmonary patients now" overall, and has become integral to Stanford's interdisciplinary CRIB (cardiac and respiratory care for infants with BPD) program, Dr. Mark said. "She follows these patients at Stanford along with the whole CRIB group, then sees them on her own for follow-up."

As a result of her training, Ms. Adney says, "knowing that I have the knowledge and experience to take on more complex patients, my colleagues now trust me and are confident in my skills. They feel comfortable sending [patients] to me much earlier. ... And they know it's much earlier. ... And they know if there's something I need help with, they will go to them instantly."

Pulmonology "really spoke to my heart," she said, recalling her pre-Stanford journey as an in-hospital medical-surgical nurse, and then, after her NP training, as an outpatient primary care PNP. "For the most part, it's like putting a puzzle together, and being able to really impact the quality of life these patients have," said Ms. Adney, who serves on the APAPP's pediatric subcommittee.

It's clear, Dr. Mark said, that "things are changing around the country" with increasing institutional interest in developing formal APP specialty training programs. "There's no way [for an APP] to walk into a specialty and play an active role without additional training," and institutions are frustrated with turnover and the loss of APPs who decide after 6-9 months of on-the-job training that they're not interested in the field.

Stanford Medicine Children's Health, in fact, has launched an internal Pediatric APP Fellowship Program that is training its first cohort of six newly graduated NPs and PAs in two clinical tracks, including a medical/surgical track that incorporates rotations in pulmonary medicine, said Raji Koppolu, CPNP-PC/AC, manager of advanced practice professional development for Stanford Medicine Children's Health.

APP fellowship programs have been in existence since 2007 in a variety of clinical settings, she said, but more institutions are developing them as a way of recruiting and retaining APPs in areas of high need and of equipping them for successful transitions to their APP roles. Various national bodies accredit APP fellowship programs.

Most pulmonary fellowship programs, Ms. Young said, are also internal programs providing post-graduate education to their own newly hired APPs or recent NP/PA graduates. This limits their reach, but "it's a step in the right direction toward standardizing education for pulmonary APPs."

Defining APP competencies

In interventional pulmonology, training may soon be guided by newly defined "core clinical competencies" for APPs. The soon-to-be published and distributed competencies – the first such national APP competencies in pulmonology – were developed by an APP Leadership Council within the American Association of Bronchology and Interventional Pulmonology (AABIP) and cover the most common disease processes and practices in IP, from COPD and bronchoscopic lung volume reduction to lung cancer screening.

Rebecca Priebe, ACNP-BC, who cochairs the AABIP's APP chapter, organized the effort several years ago, bringing together a group of APPs and physician experts in advanced bronchoscopy and IP (some but not all of whom have worked with APPs), after fielding questions from pulmonologists at AABIP meetings about what to look for in an AAP and how to train them.

Physicians and institutions who are hiring and training APPs for IP can use any or all of the 11 core competencies to personalize and evaluate the training process for each APP's needs, she said. "Someone looking to hire an APP for pleural disease, for instance, can pull up the content on plural effusion." APP interest in interventional pulmonology is growing rapidly, Ms. Priebe said, noting growth in the AABIP's APP chapter from about 7-8 APPs 5 years ago to at least 60 currently.

Ms. Priebe was hired by Henry Ford Health in Detroit about 5 years ago to help establish and run an inpatient IP consult service, and more recently, she helped establish their inpatient pleural disease service and a bronchoscopic lung volume-reduction program.

For the inpatient IP service, after several months of side-by-side training with an IP fellow and attending physicians, she began independently evaluating new patients, writing notes, and making recommendations. For patients with pleural disease, she performs ultrasound examinations, chest tube insertions, and bedside thoracentesis independently. And for the bronchoscopic lung volume-reduction program, she evaluates patients for candidate status, participates in valve placement, and sees patients independently throughout a year of follow-up.

"Physician colleagues often aren't sure what an APP's education and scope of practice is," said Ms. Priebe, who was an ICU nurse before training as an acute care NP and then worked first with a private practice inpatient service and then with the University of Michigan, Ann Arbor, where she established and grew an APP-run program managing lung transplant patients and a step-down ICU unit.

"It's a matter of knowing [your state's policies], treating them like a fellow you would train, and then using them to the fullest extent of their education and training. If they're given an opportunity to learn a subspecialty skill set, they can be an asset to any pulmonary program.”

“We’re here to support, not replace”

In her own practice, Ms. Young is one of seven APPs who work with nine physicians on a full range of inpatient care, outpatient care, critical care, sleep medicine, and procedures. Many new patients are seen first by the APP, who does the workup and orders tests, and by the physician on a follow-up visit. Most patients needing routine management of asthma and COPD are seen by the physician every third or fourth visit, she said.

Ms. Young also directs a 24-hour in-house APP service recently established by the practice, and she participates in research. In a practice across town, she noted, APPs see mainly established patients and do not practice as autonomously as the state permits. "Part of that difference may [stem from] the lack of a standard of education and variable amounts of work the practice puts into their APPs.”

The American Medical Association’s #StopScopeCreep social media messaging feels divisive and "sheds a negative light on APPs working in any area," Ms. Young said. "One of the biggest things we want to convey [at APAPP] is that we’re not here for [physicians’] jobs."

“We’re here to support those who are practicing, to support under-served populations, and to help bridge gaps” created by an aging pulmonologist workforce and real and projected physician shortages, Ms. Young said, referring to a 2016 report from the Health Resources and Services Administration (https://bhpr.hrsa.gov/sites/default/files/bureau-health-workforce-data-research/ internal-medicine-subspecialty-report.pdf) and a 2017 report from Merritt Hawkins indicating that 73% of U.S. pulmonologists (the largest percentage of all subspecialties) were at least 55 years old (https://www.merrithawkins.com/uploadedFiles/mhwhitepaperspecialties2017.pdf). Dr. Hussain said he has "seen
**COPD care bundle curbs all-cause readmissions**

**BY HEIDI SPLETE**

A multidisciplinary care bundle for chronic obstructive pulmonary disease (COPD) significantly reduced all-cause hospital readmissions at 30, 60, and 90 days, based on data from approximately 300 patients.

COPD remains a leading cause of mortality and a leading contributor to health care costs, but data suggest that adoption of an interdisciplinary care bundle could reduce hospital readmissions for COPD patients, Sibyl Cherian, PharmD, BCPS, of Overlook Medical Center, Summit, N.J., and colleagues wrote. The Centers for Medicare & Medicaid Services has introduced both penalties and bundled payments for hospitals with excess all-cause readmission rates after hospitalizations, but more data are needed on the ability of a COPD care bundle to reduce readmission for COPD.

In a study published in the Journal of the American Pharmacists Association (2022 Oct 10. doi: 10.1016/j.japh.2022.10.002), the researchers assigned 127 individuals with COPD to a COPD care bundle arm and 189 to a control arm for treatment at a single center. The standard of care group was admitted between Jan. 1 and Dec. 31, 2017; the COPD care bundle group was admitted between Jan. 1 and Dec. 31, 2018. The mean age of the participants across both groups was 72 years, and more than 70% of patients in each group were White. The COPD care bundle was managed by a team including pulmonologists, hospitalists, care managers, advanced practice nurses, pharmacists, respiratory care practitioners, physical therapists, documentation specialists, quality improvement experts, social workers, and dietitians.

The primary outcome was 30-day all-cause readmission among adults with acute exacerbation of COPD. Overall, the rate of 30-day all-cause readmissions was significantly lower in the COPD care bundle arm versus the control arm (11.8% vs. 21.7%; P = .017). Similar differences appeared between the care bundle group and control group for all-cause readmissions at 60 days (8.7% vs. 18%; P = .013) and 90 days (4.7% vs. 19.6%; P < .001).

Reasons for reduced readmissions after implementation of the COPD care bundle included pulmonary follow-up appointments of 7 days or less, significantly increased physical therapy consultations, and significant escalation of COPD maintenance therapy, the researchers wrote.

Notably, pharmacists consulted with 68.5% of patients overall and assisted with access to outpatient medications for 45.7% of those in the care bundle arm.

**OSA AND COPD** // continued from page 1

echocardiography, and polysomnography to confirm their OSA and COPD diagnoses.

The primary endpoint was the impact of OSA on functional performance and cardiac autonomic control in COPD patients, based on measures of heart rate variability and the 6-minute walk test (6MWT). Participants were followed for 1 year, with telephone contacts every 3 months. A secondary endpoint was the number of exacerbations, hospitalizations, and deaths. At baseline, OSA-COPD patients had worse polysomnographic function, compared with COPD patients; they also tended to be older and have higher body mass index, but other demographics were similar between the groups.

Overall, patients in the OSA-COPD group had significantly greater functional impairment, compared with the COPD group (P = .003), as measured by the 6MWT. The OSA-COPD patients also showed significantly worse autonomic response during exercise, compared with the COPD group.

A lower work load during exercise and the interaction between group and time factors suggests that OSA impacts the exercise capacity of COPD patients, the researchers said. Notably, however, neither age nor body mass index was associated with functional performance in the OSA-COPD group.

Patients in the OSA-COPD group also were significantly more likely to experience exacerbations during the study period, compared with the COPD-only group (67.4% vs. 23.5; P = .03). However, the severity of COPD was similar between the groups, which further illustrates that OSA can impair functional performance in COPD patients, the researchers said.

The findings were limited by several factors including the small sample size and restricted collection of follow-up data during the pandemic, the researchers noted. However, the results support previous studies, and suggest that overlapping OSA and COPD produces worse outcomes.

“Future studies can confirm our findings, providing new clinical evidences to the assessment of sleep quality in COPD patients and its implications for the general health status of these individuals. In addition to contributing to more assertive clinical and therapeutic alternative support, there is the need for more research into the mechanisms behind this overlap in larger samples to develop treatment alternatives,” they concluded.

The study was supported by the Federal University of São Carlos. The researchers had no financial conflicts to disclose.

---

**PROVIDERS continued from previous page**

Scope creep” first-hand in his hospital, in the form of noncollaborative practices and tasks performed by APPs without adequate training – most likely stemming from poor decisions and oversight by physicians. But when constructed thoughtfully, APP-physician teams are “serving great needs” in many types of care, he said, from follow-up care and management of chronic conditions to inpatient rounding. “My [colleagues] are having great success,” he said.

He is watching with interest – and some concern – pending reimbursement changes from the Centers for Medicare & Medicaid Services that will make time the only defining feature of the “substantive” portion of a split/shared visit involving physicians and APPs in a facility setting. Medical decision-making will no longer be applicable.

For time-based services like critical care, time alone is currently the metric. (And in the nonfacility setting, physician-APP teams may still apply “incident to” billing practices). But in the facility setting, said Amy M. Ahasic, MD, MPH, FCCP, a pulmonologist in Norwalk, Conn., who coauthored a 2022 commentary on the issue (Chest. 2022;162[3]:514-6), the change (now planned for 2024) could be problematic for employed physicians whose contracts are based on productivity, and could create tension and possibly lead to reduced use of APPs rather than supporting collaborative care.

“The team model has been evolving so well over the past 10-15 years,” said Dr. Ahasic, who serves on the CHEST Health Policy and Advocacy Reimbursement Workgroup and cochairs the CHEST/ATS Clinical Practice Committee with Dr. Hussain. “It’s good for patient safety to have more [providers] involved ... and because APP salaries are lower health systems could do it and be able to have better care and better coverage.”

The pulmonology culture, said Dr. Hussain, has been increasingly embracing APPs and “it’s collegial.” Pulmonologists are “coming to CHEST meetings with their APPs. The article sources reported they had no relevant conflicts.”
OSA tied to risk of atrial fibrillation and stroke

BY HEIDI SPLETE
MDedge News

Undiagnosed atrial fibrillation (AFib) was significantly more common among adults with obstructive sleep apnea (OSA), compared with controls, based on data from 303 individuals.

OSA has become a common chronic disease, and cardiovascular diseases including AFib also are known independent risk factors associated with OSA, Anna Hojager, MD, of Zealand University Hospital, Roskilde, Denmark, and colleagues wrote. Previous studies have shown a significant increase in AFib risk in OSA patients with severe disease, but the prevalence of undiagnosed AFib in OSA patients has not been explored.

In a study published in Sleep Medicine (2022 Oct 7. doi: 10.1016/j.sleep.2022.10.002), the researchers enrolled 238 adults with severe OSA (based on apnea-hypopnea index of 15 or higher) and 65 with mild or no OSA (based on an AHI of less than 15). The mean AHI across all participants was 34.2, and ranged from 0.2 to 115.8.

Participants underwent heart rhythm monitoring using a home system or standard ECG for 7 days; they were instructed to carry the device at all times except when showering or sweating heavily. The primary outcome was the detection of AFib, defined as at least one period of 30 seconds or longer with an irregular heart rhythm but without detectable evidence of another diagnosis. Sleep was assessed for one night using a portable sleep monitoring device. All participants were examined at baseline and measured for blood pressure, body mass index, waist-to-hip ratio, and ECG.

Overall, AFib occurred in 21 patients with moderate to severe OSA and 1 patient with mild/no OSA (8.8% vs. 1.5%, P = .045). The majority of patients across both groups had hypertension (66%) and dyslipidemia (77.6%), but the severe OSA group was more likely to be dysregulated and to have unknown prediabetes. Participants who were deemed candidates for anticoagulation therapy were referred for additional treatment. None of the 22 total patients with AFib had heart failure with reduced ejection fraction, and 68.2% had normal ejection fraction and ventricle function.

The researchers noted that no guidelines currently exist for systematic opportunistic screening for comorbidities in OSA patients.

Jonathan Ludmir, MD, comments: This small study highlights the strong known association between atrial fibrillation (AFib) and OSA. The American Society of Cardiology AFib guidelines provide a 2a recommendation to screen for AFib in patients with OSA. As a cardiologist, I think it is crucial to consider OSA screening for new-onset AFib, as optimal OSA management can ameliorate AFib symptoms.
Early two-thirds of patients with advanced non–small cell lung cancer (NSCLC) who are eligible for targeted therapy are not receiving these drugs because of gaps in clinical practice all along the cancer care spectrum, reveals a new analysis of data from U.S. practices. For some of these patients, it could mean missing the chance for long-term survival or even cure.

Patients who have lung cancer with mutations that can be targeted with drug therapies – but who do not receive them – are missing this opportunity. The new study suggests that there are many such patients. The researchers analyzed data on more than 38,000 patients with actively managed advanced NSCLC. They found that about half did not receive biomarker test results for a mutation that can be targeted with drug therapies – but who do not receive them – are missing this opportunity. The new study suggests that there are many such patients. The researchers analyzed data on more than 38,000 patients with actively managed advanced NSCLC. They found that about half did not receive biomarker test results for a mutation that can be targeted with drug therapies.沙丘Books的©by the American College of Chest Physicians

Predictive biomarker testing to identify patients who may benefit from targeted therapies “is a cornerstone of personalized medicine in cancer care, allowing for more rapid diagnosis while informing treatment decisions that could lead to better patient outcomes and systemic efficiencies,” the researchers emphasized. However, providers “face several challenges” when integrating biomarker testing and targeted therapeutics into cancer care, and the use of biomarker testing varies widely across tumor types, biomarkers, and practice settings.

For their study, the team examined the use of targeted therapy in advanced NSCLC using data from the Diaceutics Data Repository, which includes commercial and Medicare claims, as well as laboratory data. They focused on 38,068 patients with actively managed advanced NSCLC. Of those patients, 50.80% were women, and 64.6% were aged 71 years or older. The vast majority (84.50%) were non-Hispanic White patients.

They then normalized the results to a standard patient population of 1,000. In 6.6% of cases, an initial tissue or liquid biopsy was never performed, meaning that 66 of the 1,000 patients could not progress toward targeted therapy.

Among those who underwent a biopsy, for 4.0%, there was insufficient tissue on the initial biopsy, while for a further 0.97%, there was insufficient tissue on re-biopsy. Moreover, 9.6% could not undergo biopsy testing because of a lack of tumor tissue. Consequently, a further 136 of the 944 remaining patients were lost.

For the third clinical practice gap, the tumor cell content was overestimated in 1.7% of patients. As a result, their biopsy specimen could not be tested because it did not meet the threshold requirements. Moreover, for a further 17.5% of patients, biomarker testing was not ordered at all, owing to cost concerns, a lack of access to testing, a lack of awareness of testing options, and low confidence in the results, among other reasons. An additional 0.6% began treatment before any testing was ordered. Even among patients who underwent biomarker testing, 14.5% had uninformative or inconclusive results, and 3.9% had false-negative results.

In another 4.0% of cases, the results of biomarker testing did not arrive within the treatment decision window, because of delays in reporting the results, and so for these patients, treatment began without the results being taken into consideration. The final clinical practice gap was not choosing the appropriate targeted treatment on the basis of test results. The researchers found that of 27,186 patients who underwent biomarker testing and received a timely result, 29.2% were not given the appropriate targeted therapy. Overall, the team calculated that 64.4% of patients newly diagnosed with advanced NSCLC “are not benefiting from precision oncology care options appropriate for their diseases and will likely have suboptimal outcomes.” The research was supported in part by the Personalized Medicine Coalition, a nonprofit 501(c)3 organization dedicated to the advancement of personalized medicine. Dr. Pritchard is an employee of the Personalized Medicine Coalition.
INFECTIONOUS DISEASES

Newer agents for nosocomial pneumonia: The right drug for the right bug

BY WALTER ALEXANDER
MDedge News

FROM CHEST 2022 * “The right drug at the right time with the right dose for the right bug for the right duration.” That, said professor Kristina Crothers, MD, is the general guidance for optimizing antibiotic use (while awaiting an infectious disease consult). In her oral presentation at the annual meeting of the American College of Chest Physicians, “Choosing Newer Antibiotics for Nosocomial Pneumonia,” Dr. Crothers asked the question: “Beyond the guidelines: When should novel antimicrobials be used?”

Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) are the most common nosocomial infections at 22%, and are the leading cause of death attributable to hospital-acquired infections. They increase mortality by 20%-50%, with an economic burden of about $40,000 per patient. The incidence of multidrug-resistant (MDR) organism infections varies widely by locality, but several factors increase the likelihood: prior broad-spectrum antibiotic exposure within the past 90 days; longer hospitalization; indwelling vascular devices; tracheostomy; and ventilator dependence. The Centers for Disease Control and Prevention lists as “Serious Threat” the HAP/VAP MDR organisms methicillin resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa (PA) with difficult-to-treat-resistance, and beta-lactamase producing Enterobacteriales (ESBL). In the category of “Urgent Threat” the CDC lists carbapenemase-resistant Enterobacteriales (CRE) (carbapenemase producing or non–carbapenemase producing), and carbapenem-resistant Actinobacteriales (CRAB), according to Dr. Crothers of the University of Washington Veterans Affairs Puget Sound Health Care System, Seattle.

Newer antibiotics for HAP/VAP that are still beyond the guidelines include telavancin and tezidolizid as gram-positive agents, and as gram-negative ones: ceftazidime-avibactam, cefotolozane-tazobactam, cefiderocol, imipenem-cilastatin-relebactam, and meropenem-vaborbactam, she added.

Tezidolizid, Dr. Crothers stated, is a novel oxazolidinone, and is an alternative to vancomycin and linezolid for gram-positive HAP/VAP. In the VITAL noninferiority study versus linezolid with 726 patients, it was noninferior to linezolid for 28-day all-cause mortality (28% vs. 26%), but did not achieve noninferiority for investigator-assessed clinical cure (56% vs. 64%).

Telavancin, a semisynthetic derivative of vancomycin, in the ATTAIN studies vs. vancomycin had overall similar cure rates. It is FDA-approved for S. aureus HAP/VAP but not other bacterial causes. It should be reserved for those who cannot receive vancomycin or linezolid, with normal renal function, according to Dr. Crothers.

Excluded from first-line treatment of gram-positive HAP/VAP are daptomycin, ceftaroline, cefobiprole, and tigecycline.

Ceftazidime-avibactam, a third-generation cephalosporin-plus novel beta-lactamase inhibitor has wide activity (Klebsiella pneumoniae, Enterobacter cloaceae, Escherichia coli, Serratia marcescens, Proteus mirabilis, PA, and Hae mophillus influenzae). It is also active against some extended-spectrum beta-lactamases, ampC beta-lactamases (ampCs), and K. pneumoniae carbapenemase (KPC)–producing Enterobacteriales, but not with metallo-beta-lactamases. Ceftazidime-avibactam is also indicated for HAP/VAP, and has a toxicity profile including nausea, vomiting, and diarrhea.

In the REPROVE trial of ceftazidime-avibactam vs. meropenem for 7-14 days with 527 evaluable patients (37% K. pneumoniae, 30% P. aeruginosa, and 33%-35% VAP), the clinical cure at 21-25 days post randomization was 69% vs. 73%, respectively, with similar adverse events.

Ceftolozane-tazobactam, a novel fifth-generation cephalosporin plus a beta-lactamase inhibitor has activity against PA including extensively drug-resistant PSA, AmpC, and ESBL-E, but it has limited activity against Acinetobacter and Stenotrophomonas. It is indicated for HAP/VAP, has reduced efficacy with creatine clearance of 50 ml/min or less, increases transaminases and renal impairment, and causes diarrhea. In ASPECT-NP (n = 726) ceftolozane-tazobactam versus meropenem for 8-14 days (HAP/VAP), showed a 28 day-mortality of 24% vs. 25%, respectively, with test of cure at 54% vs. 53% at 7-14 days post therapy. Adverse events were similar between groups.

Imipenem-cilastatin-relebactam, a novel beta-lactamase inhibitor plus carbapenem, is indicated for HAP/VAP and has activity against ESBL, CRE, KPC-producing Enterobacteriales, and PSA including AmpC. It can cause seizures (requires caution with central nervous system disorders and renal impairment). It increases transaminases, anemia, and diarrhea, and reduces potassium and sodium. In RESTORE-IMI 2 (n = 537 with HAP/VAP) it was noninferior for 28-day all-cause mortality vs. piperacillin and tazobactam (16% vs. 21%), with similar adverse events.

Cefiderocol, a siderophore cephalosporin, is indicated for HAP/VAP. It has a wide spectrum of activity: ESBL, CRE, CR PSA, Stenotrophomonas maltophilia, Acinetobacter baumannii, Streptococcus. It increases transaminases, diarrhea, and renal fibration, and it reduces potassium and magnesium.

In APEKS-NP versus linezolid plus cefiderocol or extended meropenem infusion (HAP/VAP n = 292; gram-negative pneumonia = 251; 60 invasive mechanical ventilation) it was noninferior for 14-day all-cause mortality (12.4% vs. 11.6%) with similar adverse events. In CREDIBLE-CR vs. best available therapy for carbapenem-resistant gram-negative infections, clinical cure rates were similar (50% vs. 53% in 59 HAP/VAP patients at 7 days), but with more deaths in the cefidercol arm. Adverse events were > 90% in both groups and 34% vs. 19% died, mostly with Acinetobacter.

Meropenem-vaborbactam, a novel beta-lactamase inhibitor plus carbapenem, is approved and indicated for HAP/VAP in Europe. It has activity against MDR, Enterobacteriales including CRE. Its toxicities include headache, phlebitis/infusion-site reactions and diarrhea. In TANGO-2 versus best available treatment for CRE (n = 77, 47 with confirmed CRE), clinical cure was increased and mortality decreased compared with best available therapy. Treatment-and renal-related adverse events were lower for meropenem-vaborbactam.

In closing, Dr. Crothers cited advice from the paper by Tamma et al. (“Rethinking how antibiotics are prescribed” JAMA. 2019; 32[2]:139-40) about the need to review findings after therapy has been initiated to confirm the pneumonia diagnosis: Novel agents should be kept in reserve in the absence of MDR risk factors for MRSA and gram-negative bacilli; therapy should be deescalated after 48-72 hours if MDR organisms are not detected; and therapy should be directed to the specific organism detected. Most HAP and VAP in adults can be treated for 7 days, she added.

“Know indications for new therapeutic agents approved for nosocomial pneumonia,” she concluded.

Dr. Crothers reported having no disclosures.
INFECTION DISEASE

Study affirms shorter regimens for resistant TB

By Kate Johnson

Two short-course treatments containing bedaquiline for rifampicin-resistant tuberculosis showed “robust evidence” for superior efficacy and less ototoxicity compared to a 9-month injectable control regimen, researchers report.

The findings validate the World Health Organization’s current recommendation of a 9-month, bedaquiline-based oral regimen, “which was based only on observational data,” noted lead author Ruth Goodall, PhD, from the Medical Research Council Clinical Trials Unit at University College London, and colleagues.

The study was published in The Lancet (2022 Nov 8. doi: 10.1016/S0140-6736(22)02078-5).

The Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB (STREAM) stage 2 study was a randomized, phase 3, noninferiority trial conducted at 13 hospital clinics in seven countries that had prespecified tests for superiority if noninferiority was shown. The study enrolled individuals aged 15 years or older who had rifampicin-resistant TB without fluoroquinolone or aminoglycoside resistance.

The study’s first stage, STREAM stage 1, showed that a 9-month injectable regimen was noninferior to the WHO’s 2011 recommendation of a 20-month injectable regimen. The 9-month regimen was recommended by the WHO in 2016. That recommendation was superseded in 2020 when concerns to the WHO’s 2011 recommendation of a 9-month, injectable-free alternative, the authors write.

Seeking shorter treatment for better outcomes

STREAM stage 2 used a 9-month injectable regimen as its control. The investigators measured it against a fully oral 9-month bedaquiline-based treatment (primary comparison), as well as a 6-month oral bedaquiline regimen that included 8 weeks of a second-line injectable (secondary comparison).

The 9-month fully oral treatment included levofloxacin, clofazimine, ethambutol, and pyrazinamide for 40 weeks; bedaquiline, high-dose isoniazid, and prothionamide were given for the 16-week intensive phase.

The 6-month regimen included bedaquiline, clofazimine, pyrazinamide, and levofloxacin for 28 weeks, supplemented by high-dose isoniazid with kanamycin for an 8-week intensive phase.

For both comparisons, the primary outcome was favorable status at 76 weeks, defined as cultures that were negative for Mycobacterium tuberculosis without a preceding unfavorable outcome (defined as any death, bacteriologic failure or recurrence, or major treatment change).

Among 517 participants in the
modified intention-to-treat population across the study groups, 62% were men, and the median age was 32.5 years.

For the primary comparison, 71% of the control group and 83% of the oral regimen group had a favorable outcome.

In the secondary comparison, 69% had a favorable outcome in the control group, compared with 91% of those receiving the 6-month regimen.

Although the rate of grade 3 or 4 adverse events was similar in all three groups, there was significantly less ototoxicity among patients who received the oral regimen, compared with control patients (2% vs. 9%); 4% of those taking the 6-month regimen had hearing loss, compared with 8% of control patients.

Exploratory analyses comparing both bedaquiline-containing regimens revealed a significantly higher proportion of favorable outcomes among participants receiving the 6-month regimen (91%), compared with patients taking the fully oral 9-month regimen (79%). There were no significant differences in the rate of grade 3 or 4 adverse events.

The trial’s main limitation was its open-label design, which might have influenced decisions about treatment change, note the investigators.

“STREAM stage 2 has shown that two short-course, bedaquiline-containing regimens are not only..."
treatment options for patients with MDR or rifampicin-resistant tuberculosis," the authors write.

Dr. Goodall added, "Although both STREAM regimens were very effective, participants experienced relatively high levels of adverse events during the trial (though many of these were likely due to the close laboratory monitoring of the trial)."

“While hearing loss was reduced on the 6-month regimen, it was not entirely eliminated," she said. "Other new regimens in the field containing the medicine linezolid report side effects such as anemia and peripheral neuropathy. So more work needs to be done to ensure the treatment regimens are as safe and tolerable for patients as possible. In addition, even 6 months' treatment is long for patients to tolerate, and further regimen shortening would be a welcome development for patients and health systems."

A ‘revolution’ in MDR tuberculosis

"The authors must be commended on completing this challenging

**IMPORTANT SAFETY INFORMATION**

**WARNINGS AND PRECAUTIONS (CONT'D) - Gastrointestinal Disorders (cont'd)**

**Diarrhea (cont'd)**

- In the chronic fibrosing ILDs with a progressive phenotype study, diarrhea was reported in 67% versus 24% of patients treated with OFEV and placebo, respectively. Diarrhea led to permanent dose reduction in 16% and discontinuation in 6% of OFEV patients, compared to less than 1% of placebo-treated patients, respectively.
- In the SSC-ILD study, diarrhea was the most frequent gastrointestinal event reported in 76% versus 32% of patients treated with OFEV and placebo, respectively. Diarrhea led to permanent dose reduction in 22% and discontinuation in 7% of OFEV patients versus 1% and 0.3% in placebo patients, respectively.
- Dosage modifications or treatment interruptions may be necessary in patients with diarrhea. Treat diarrhea at first signs with adequate hydration and antiarrhythmic medication (e.g., loperamide), and consider dose reduction or treatment interruption if diarrhea continues. OFEV treatment may be resumed at the full dosage (150 mg twice daily), or at the reduced dosage (100 mg twice daily), which subsequently may be increased to the full dosage. If severe diarrhea persists, discontinue treatment.

**Nausea and Vomiting**

- In IPF studies, nausea was reported in 24% versus 7% and vomiting was reported in 12% versus 3% of patients treated with OFEV and placebo, respectively. Nausea and vomiting led to discontinuation of OFEV in 2% and 1% of patients, respectively.
- In the chronic fibrosing ILDs with a progressive phenotype study, nausea was reported in 29% versus 9% and vomiting was reported in 18% versus 5% of patients treated with OFEV and placebo, respectively. Nausea led to discontinuation of OFEV in less than 1% of patients, and vomiting led to discontinuation of OFEV in 1% of the patients.
- In the SSC-ILD study, nausea was reported in 32% versus 14% and vomiting was reported in 25% versus 10% of patients treated with OFEV and placebo, respectively. Nausea and vomiting led to discontinuation of OFEV in 2% and 1% of patients, respectively.
- In most patients, events were primarily of mild to moderate intensity. If nausea or vomiting persists despite appropriate supportive care including antiemetic therapy, consider dose reduction or treatment interruption. OFEV treatment may be resumed at full dosage or at reduced dosage, which subsequently may be increased to full dosage. If severe nausea or vomiting does not resolve, discontinue treatment.

**Embryo-Fetal Toxicity:** OFEV can cause fetal harm when administered to a pregnant woman and patients should be advised of the potential risk to a fetus. Women should be advised to avoid becoming pregnant while receiving OFEV and to use highly effective contraception at initiation of treatment, during treatment, and at least 3 months after the last dose of OFEV. Nintedanib does not change the exposure to oral contraceptives containing ethinylestradiol and levonorgestrel in patients with SSC-ILD. However, the efficacy of oral hormonal contraceptives may be compromised by vomiting and/or diarrhea or other conditions where drug absorption may be reduced. Advise women taking oral hormonal contraceptives experiencing these conditions to use alternative highly effective contraception. Verify pregnancy status prior to starting OFEV and during treatment as appropriate.

**Arterial Thromboembolic Events**

- In IPF studies, arterial thromboembolic events were reported in 2.5% of OFEV and less than 1% of placebo patients, respectively. Myocardial infarction (MI) was the most common arterial thromboembolic event, occurring in 1.5% of OFEV and in less than 1% of placebo patients.
- In the chronic fibrosing ILDs with a progressive phenotype study, arterial thromboembolic events and MI were reported in less than 1% of patients in both treatment arms.
- In the SSC-ILD study, arterial thromboembolic events were reported in 0.7% of patients in both the OFEV-treated and placebo-treated patients. There were 0 cases of MI in OFEV-treated patients compared to 0.7% of placebo-treated patients.
- Use caution when treating patients who have had cardiovascular risk, including known coronary artery disease. Consider treatment interruption in patients who develop signs or symptoms of acute myocardial ischemia.

**Risk of Bleeding**

- OFEV may increase the risk of bleeding.
- In IPF studies, bleeding events were reported in 10% of OFEV versus 7% of placebo patients.
- In the chronic fibrosing ILDs with a progressive phenotype study, bleeding events were reported in 11% of OFEV versus 13% of placebo patients.
- In the SSC-ILD study, bleeding events were reported in 11% of OFEV versus 8% of placebo patients.
- In clinical trials, epistaxis was the most frequent bleeding event. There have been post-marketing reports of non-serious and serious bleeding events, some of which were fatal. Use OFEV in patients with known risk of bleeding only if the anticipated benefit outweighs the potential risk.

**Gastrointestinal Perforation**

- OFEV may increase the risk of gastrointestinal perforation.
- In IPF studies, gastrointestinal perforation was reported in less than 1% of OFEV versus in 0% of placebo patients.
- In the chronic fibrosing ILDs with a progressive phenotype study, gastrointestinal perforation was not reported in any treatment arm.
- In the SSC-ILD study, no cases of gastrointestinal perforation were reported in either OFEV or placebo-treated patients.
high-quality, phase 3, randomized controlled trial involving 13 health care facilities across Ethiopia, Georgia, India, Moldova, Mongolia, South Africa, and Uganda ... despite the COVID-19 pandemic,” noted Keertan Dheda, MD, PhD, and Christoph Lange, MD, PhD, in an accompanying comment titled, “A revolution in the management of multidrug-resistant tuberculosis” (Lancet. 2022; Nov 8. doi: 10.1016/S0140-6736(22)02161-4).

Although the WHO recently approved an all-oral 6-month bedaquiline, pretomanid, and linezolid plus moxifloxacin (BPaLM) regimen, results from the alternate 6-month regimen examined in STREAM stage 2 “do provide confidence in using 2 months of an injectable as part of a salvage regimen in patients for whom MDR tuberculosis treatment is not successful” or in those with extensively drug-resistant or pre-XDR TB, “for whom therapeutic options are few,” noted Dr. Dheda, who is from the University of Cape Town (South Africa) and the London School of Hygiene and Tropical Medicine, and Dr. Lange, from the University of Lübeck (Germany), Baylor College of Medicine, and Texas Children’s Hospital, both in Houston.

Both the study authors and the commentators stressed that safer and simpler treatments are still

IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS (CONT’D)
Gastrointestinal Perforation (cont’d)
• In the post-marketing period, cases of gastrointestinal perforations have been reported, some of which were fatal. Use caution when treating patients who have had recent abdominal surgery, have a previous history of diverticular disease, or who are receiving concomitant corticosteroids or NSAIDs. Discontinue therapy with OFEV in patients who develop gastrointestinal perforation. Only use OFEV in patients with known risk of gastrointestinal perforation if the anticipated benefit outweighs the potential risk.

Nephrotic Range Proteinuria: Cases of proteinuria within the nephrotic range have been reported in the postmarketing period. Histological findings, when available, were consistent with glomerular microangiopathy with or without renal thrombi. Improvement in proteinuria has been observed after OFEV was discontinued; however, in some cases, residual proteinuria persisted. Consider treatment interruption in patients who develop new or worsening proteinuria.

ADVERSE REACTIONS
Adverse Reactions observed in clinical trials were as follows:
Idiopathic Pulmonary Fibrosis
• The most common adverse reactions reported (greater than or equal to 5%) were diaphoresis, nausea, abdominal pain, liver enzyme elevation, vomiting, decreased appetite, weight decreased, headache, and hypertension.
• The most frequent serious adverse reactions reported in patients treated with OFEV, more than placebo, were bronchitis (1.2% vs. 0.8%) and MI (1.5% vs. 0.4%). The most common adverse events leading to death in OFEV patients versus placebo were pneumonia (0.7% vs. 0.6%), lung neoplasm malignant (0.3% vs. 0.3%), and myocardial infarction (0.3% vs. 0.2%). In the predefined category of major adverse cardiovascular events (MACE) including MI, fatal events were reported in 0.6% of OFEV versus 1.8% in placebo patients.

Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype
• The most common adverse reactions were consistent with those observed in IPF and also included nasopharyngitis, upper respiratory infection, urinary tract infection, fatigue and back pain.
• The most frequent serious adverse event reported in patients treated with OFEV, more than placebo, was pneumonia (4% vs. 3%). Adverse events leading to death were reported in 5% of OFEV patients and in 5% of placebo patients. No pattern was identified in the adverse events leading to death.

Systemic Sclerosis-Associated Interstitial Lung Disease
• The most common adverse reactions reported (greater than or equal to 5%) were diarrhea, nausea, vomiting, skin ulcer, abdominal pain, liver enzyme elevation, weight decreased, fatigue, decreased appetite, headache, pyrexia, back pain, dizziness, and hypertension.

Copyright ©2022, Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved. (03/22) PC-US-121750A

Boehringer
Ingelheim

• The most frequent serious adverse events reported in patients treated with OFEV, more than placebo, were interstitial lung disease (2.4% vs. 1.7%) and pneumonia (2.8% vs. 0.3%). Within 52 weeks, 5 patients treated with OFEV (1.7%) and 4 patients treated with placebo (1.4%) died. There was no pattern among adverse events leading to death in either treatment arm.

DRUG INTERACTIONS
• P-glycoprotein (P-gp) and CYP3A4 Inhibitors: Coadministration with oral doses of a P-gp and CYP3A4 inhibitor, ketoconazole, increased exposure to nintedanib by 60%. Concomitant use of potent P-gp and CYP3A4 inhibitors (e.g., erythromycin) with OFEV may increase exposure to nintedanib. In such cases, patients should be monitored closely for tolerability of OFEV. Management of adverse reactions may require interruption, dose reduction, or discontinuation of therapy with OFEV. Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. Concomitant use of P-gp and CYP3A4 inducers (e.g., carbamazepine, phenytoin, and St. John’s wort) with OFEV should be avoided as these drugs may decrease exposure to nintedanib.
• Anticoagulants: Nintedanib may increase the risk of bleeding. Monitor patients on full anticoagulation therapy closely for bleeding and adjust anticoagulation treatment as necessary.

USE IN SPECIFIC POPULATIONS
• Nursing Mothers: Because of the potential for serious adverse reactions in nursing infants from OFEV, advise women that breastfeeding is not recommended during treatment.

• Reproductive Potential: OFEV may reduce fertility in females of reproductive potential.

• Smokers: Smoking was associated with decreased exposure to OFEV, which may affect the efficacy of OFEV. Encourage patients to stop smoking prior to and during treatment.

INDICATIONS
OFEV is indicated in adults for:
• Treatment of idiopathic pulmonary fibrosis (IPF).
• Treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.
• Slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).

Please see accompanying Brief Summary of Prescribing Information on the following pages.

RESISTANT continued from previous page

"Therefore, if we are to protect key drugs from becoming functionally redundant, drug-susceptibility testing capacity will need to be rapidly improved to minimize resistance amplification and onward disease transmission."

The study was funded by USAID and Janssen Research and Development. Dr. Goodall has disclosed no relevant financial relationships. Dr. Dheda has received funding from the EU and the South African Medical Research Council for studies related to the diagnosis or management of drug-resistant tuberculosis. Dr. Lange is supported by the German Center for Infection Research and has received funding from the European Commission for studies on the development of novel antituberculosis medicines and for studies related to novel diagnostics of tuberculosis; consulting fees from INSMD; and speaker's fees from INSMD, GILEAD, and Janssen; and is a member of the data safety board of trials from Medicines Sans Frontiers, all of which are unrelated to the current study.

| Table 1 Adverse Reactions Occurring in ≥2% of Patients Treated with Placebo or OFEV (N=508) and Placebo- or OFEV-Treated Patients, by Body System
<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Body System</td>
</tr>
<tr>
<td>Cerebrovascular disorders</td>
</tr>
<tr>
<td>Cardiac disorders</td>
</tr>
<tr>
<td>Endocrine disorders</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
</tr>
<tr>
<td>General disorders</td>
</tr>
<tr>
<td>Hematological disorders</td>
</tr>
<tr>
<td>Injury, poisoning and procedural complications</td>
</tr>
<tr>
<td>Metabolic and nutritional disorders</td>
</tr>
<tr>
<td>Nervous system disorders</td>
</tr>
<tr>
<td>Ophthalmic disorders</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
</tr>
<tr>
<td>Urogenital disorders</td>
</tr>
</tbody>
</table>

OFEV (nintedanib) capsules, for oral use

BRIEF SUMMARY OF PRESCRIBING INFORMATION

Please see full prescribing information for full Prescribing Information, including Patient Information

1 INDICATIONS AND USAGE: 1.1 Idiopathic Pulmonary Fibrosis: OFEV is indicated for the treatment of adults with idiopathic pulmonary fibrosis (IPF). 1.2 Chronic Fibrotic Interstitial Lung Diseases with a Progressive Phenotype: OFEV is indicated for the treatment of adults with chronic fibrotic interstitial lung disease (CILD) with a progressive phenotype, 1.3 Systemic Sclerosis-Associated Interstitial Lung Disease: OFEV is indicated to slow 2 years of disease progression in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD). 2 DOSAGE AND ADMINISTRATION: 2.1 Testing Prior to OFEV Administration: Conduct liver function tests in all patients and a pregnancy test in females of reproductive potential prior to initiating treatment with OFEV (see Warnings and Precautions). 2.2 Recommended Dosage: The recommended dosage of OFEV is 150 mg taken once daily, approximately 12 hours apart. Administration Information: OFEV capsules should be taken with food and swallowed whole while liquid. OFEV capsules should not be chewed or crushed because coalescent after water tests. OFEV capsules should not be opened or crushed. If contact with the content of the capsule occurs, wash hands immediately and thoroughly. Effect of chelating or crushing of the capsule on the pharmacokinetics of nintedanib is not known. Information for Minors: If a dose of OFEV is missed, the next dose should be taken at the next scheduled time. Advise the patient not to make up for a missed dose. Do not exceed the recommended maximum daily dosage of 300 mg. 2.3 Recommended Dosage for Patients with Hepatic Impairment: Mild Hepatic Impairment: In patients with chronic hepatic impairment, adjust the dosage of OFEV to 100 mg twice daily. OFEV capsules should be taken immediately after a meal. 2.4 Dosage Modification due to Adverse Reactions: In addition to symptomatic treatment, if applicable, the management of adverse reactions may include dose reduction or temporary interruption until the specific adverse reaction resolves to levels that allow continuation of therapy. OFEV treatment may be resumed at the full dosage (150 mg twice daily), or at a reduced dosage (100 mg twice daily), which subsequently may be increased to the full dosage. If a patient does not tolerate 100 mg twice daily, discontinue treatment with OFEV (see Warnings and Precautions). 3 Adverse Reactions: OFEV is intended for the treatment of chronic lung disease (CILD) with a progressive phenotype, 5.1 Gastrointestinal Disorders: OFEV may cause nausea and vomiting. In a Phase IV efficacy maintenance study (Study 5), nausea was reported in 32% versus 14% of patients treated with OFEV and placebo, respectively (see Adverse Reactions). Diarrhea led to discontinuation of OFEV treatment in 1% of patients compared to 0.3% of placebo-treated patients. 5.3 Gastrointestinal Disorders: Diarrhea is a common adverse reaction and can lead to dose reductions. 6.1 Clinical Trials Experience:

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>OFEV (n=508)</th>
<th>Placebo (n=508)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea</td>
<td>32%</td>
<td>14%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>12%</td>
<td>3%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>16%</td>
<td>0.7%</td>
</tr>
<tr>
<td>Abdominal distention</td>
<td>10%</td>
<td>2.7%</td>
</tr>
<tr>
<td>Flatulence</td>
<td>7%</td>
<td>1.4%</td>
</tr>
<tr>
<td>Diarrhea led to discontinuation of OFEV in 1% of patients treated with OFEV and in 0.3% of placebo-treated patients.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
COPD  
Nitrogen test predicts decline in lung function  
BY HEIDI SIPLE
MDedge News

The slope of the alveolar plateau on the single-breath nitrogen test (SNB) was a significant predictor of lung function decline and of chronic obstructive pulmonary disease (COPD), based on data from 907 adults.

In recent years, interest in small-airways disease has renewed, with research suggesting a link between SAD pathology and COPD progression, wrote Francesco Pistelli, MD, of the University of Pisa (Italy) and colleagues.

The SNB has been used to detect early SAD, but few studies have examined the relationship between SNB, measures and lung function decline over time, they said.

Decline continued on following page
In a study published in Pulmonol- 
yery (2022 Oct 7: doi: 10.1016/j.pul-
10,001), the researchers reviewed data from adults aged 20
years and older who were enrolled in the Po River Delta prospective
study in Italy. The study population included 907 individuals, with a
mean age of 37.4 years; 56% were male.

The primary outcome was a change in lung function and inci-
dence of COPD during an 8-year follow-up period. COPD was
defined using either the Global
Initiative for Chronic Obstructive Lung Disease (GOLD) or American
Thoracic Society/ European Respi-
ratory Society criteria.

In a multimodal regression
model, one SBN, index, the slope
of alveolar plateau (N_{2}-slope) was
significantly associated with rates
of forced expiratory volume in 1 second (FEV1) decline, with a
decrease of 7.93 mL/year for each
one-unit change in N_{2}-slope. The
N_{2}-slope also was signifi-
cantly associated with an increased
risk of COPD, with a relative risk of
1.81 for mild obstruction and
2.78 for severe obstruction based
on GOLD criteria. The association was similar for COPD based on
the ATS-ERS criteria, with a relative
risk of 1.62 for mild obstruction
and 3.40 for moderate to severe
obstruction.

“Pulmonologists could rediscover an ‘old’ test, which could provide important
information on their patients at risk for developing COPD.”

Age was associated with an increased COPD risk using the
GOLD criteria, but not the ATS-
ERS criteria; neither sex nor current
or former smoking were associated
with increased COPD risk for either
measure. The results are consistent with
some previous longitudinal studies,
but not others, possibly because of
differences in sampling proce-
dures, test techniques, or statistical
approaches, the researchers wrote in
their discussion.

The study findings were limited by
several factors, including incomplete
data on closing capacity and vital
capacity, and by the lack of bronchodilator for perform-
ing baseline spirometry, since broncho-
dilator testing was not recommended at
the time of the study, the researchers noted.

However, the results support the
role of SAD as a contributor to
COPD, and the potential value of
the SBN_{2} test, they said. “Large
prospective studies are needed to
evaluate whether new proposed
functional or imaging tests that
measure small airways impair-
ment may be useful in the early
detection of COPD,” they noted.

In the meantime, “pulmonolo-
gists could rediscover an ‘old’ test, which could provide important
information on their patients at
risk for developing COPD,” they concluded.

The study was supported in part by
the National Research Council
Targeted Project and the Italian
Electric Power Authority. The
researchers had no financial con-
licts to disclose.
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report is revised annually and is used widely throughout the world as a tool for implementing effective management.

Among the updates in the 2023 GOLD Report, the section on diagnostic criteria added a proposed new category “PRISm,” denoting “preserved ratio impaired spirometry,” encompassing individuals who present with structural lung lesions (for example, emphysema) and/or other physiological abnormalities such as low-normal forced expiratory volume in 1 second (FEV₁), gas trapping, hyperinflation, reduced lung diffusing capacity, and/or rapid FEV₁ decline, but without trapping, hyperinflation, reduced lung diffusing capacity, and/or rapid FEV₁ decline, but without airflow obstruction (FEV₁/FEV ≥ 0.7 post bronchodilation). Some of these “pre-COPD” (chronic obstructive pulmonary disease) individuals, who have a normal ratio but abnormal spirometry are at risk over time of developing airflow obstruction. The best treatment for them, beyond smoking cessation, needs to be determined through research, the report states.

Clinical updates
The 2023 GOLD Report also offers proposed clinical guidance, in the absence of high-quality clinical trial evidence, on initial pharmacologic management of COPD. The proposal is based on individual assessment of symptoms and exacerbation risk following use of the ABE Assessment Tool, a revised version of the ABCD Assessment Tool that recognizes the clinical relevance of exacerbations independent of symptom level.

These updates to information and figures pertaining to initial pharmacological treatment and follow-up pharmacological treatment revise the positioning of LABA (long-acting beta₂ agonists) plus LAMA (long-acting muscarinic agonists) and LAMA/ICS (inhaled corticosteroids). Among GOLD group A patients with 0 or 1 moderate exacerbations that do not lead to hospital admission, a bronchodilator is recommended.

The recommendation for group B patients is LABA/LAMA with the caveat that single-inhaler therapy may be more convenient and effective than multiple inhalers. For group E patients with two or more moderate exacerbations or one or more leading to hospitalization, LABA/LAMA is recommended (with the same inhaler therapy caveat). With blood eosinophil levels at 300 or higher, LABA/LAMA/ICS may be considered. Commenting on the combination recommendations in a press release, Antonio Anzueto, MD, professor of medicine, pulmonary critical care, University of Texas Health, San Antonio, stated: “From a physician’s perspective, we are always grateful to receive well-vetted and informed recommendations on how we can best utilize available treatment options to provide the most benefit to our patients. The new 2023 GOLD recommendations represent a meaningful change for the treatment of COPD by prioritizing the utilization of a fixed LAMA/LABA combination.”

More interventions
In a section on therapeutic interventions to reduce COPD mortality, the report lists studies showing mortality benefits for fixed-dose inhaled triple combinations (LABA + LAMA + ICS) versus dual inhaled long-acting bronchodilators, and for smoking cessation and pulmonary rehabilitation.

Also new is a strong emphasis on inhaler choice, education, and technique training with assessment of inhaler technique and adherence urged as a prerequisite to judging whether current therapy as insufficient. The report summarizes principles guiding inhaler type selection.

The report also added a section on chronic bronchitis, defining it as a common but variable condition in COPD patients with cough and expectorated sputum on a regular basis over a defined period in the absence of other conditions plausibly causing symptoms.

The fact that chronic bronchitis is sometimes found in never-smokers suggests the involvement of other factors such as exposure to inhaled dusts, biomass fuels, chemical fumes, or domestic heating and cooking fuels, according to the report. Gastroesophageal reflux may also be associated with chronic bronchitis.

The report discusses various taxonomic terms for different types of COPD, such as COPD-G for genetically determined COPD, COPD-D for those with abnormal lung development, and COPD-C for COPD associated with cigarette smoking.

Change in exacerbations
The report also revises the definition of a COPD exacerbation as “an event characterized by increased dyspnea and/or cough and sputum that worsens in less than 14 days which may be accompanied by tachypnea and/or tachycardia and is often associated with increased local and systemic inflammation caused by infection, pollution, or other insult to the airways.” To overcome limitations conferred by the current grading of COPD exacerbations, the 2023 report proposes a four-step point-of-contact diagnosis and assessment tool.

Telemedicine
Given the constraints brought on by COVID-19 on top of the generally sparse availability of programs and facilities for delivering well-proven pulmonary rehabilitation methods, tele-rehabilitation has been proposed as an alternative to traditional approaches. While the evidence base is still evolving and best practices have not yet been established, the GOLD Report calls for better understanding of barriers to tele-rehabilitation success.

Comorbidities update
The GOLD Report chapter on COPD and comorbidities was also updated, and lists cardiovascular disease, lung cancer, osteoporosis, depression/ anxiety, and gastroesophageal reflux disease as common comorbid conditions which may affect prognosis and, in the case of cancer, mortality. The report urges simplicity of treatment to minimize polypharmacy. While annual low-dose CT is recommended for COPD caused by smoking, it is not recommended for COPD not caused by smoking; data are insufficient to establish benefit over harm.

While the GOLD Report “COVID-19 and COPD” chapter summarizes current evidence stating that individuals with COPD do not seem to be at substantially greater risk of infection with SARS-CoV-2, it underscores that they are at higher risk of hospitalization for COVID-19 and may be at higher risk for developing severe disease and death. Many other topics are included in the updated report, among them screening, imaging, vaccinations, adherence to therapy, and surgical and bronchoscopic interventions. In its closing section, the 2023 GOLD Report reiterates its mission, stating: “The GOLD initiative will continue to work with National Leaders and other interested health care professionals to bring COPD to the attention of governments, public health officials, health care workers, and the general public, to raise awareness of the burden of COPD and to develop programs for early detection, prevention and approaches to management.”
CHEST President shares inside look at priorities, plans for 2023

Attendees at the CHEST 2022 Opening Session on October 16 got a sneak peek into plans and priorities for CHEST President Doreen J. Addrizzo-Harris, MD, FCCP, in 2023 — and some insights into her own path to the role.

A longtime leader at CHEST, she shared how members’ pandemic response reminded her of the great impact the organization can have. In March 2020, Dr. Addrizzo-Harris was overseeing ICU staffing at NYU Langone Health’s Bellevue Hospital Center and organizing dozens of volunteer physicians to help meet the pandemic care burden.

“T knew all too quickly that we wouldn’t have enough intensivists,” said Dr. Addrizzo-Harris. “It was a quick call very late one night, probably around 1 am, that I made to CHEST CEO, Bob Musacchio, that helped materialize a monumental effort ... many of these physicians were CHEST members themselves. They were fearless and unselfish, and they came to help us in our time of need.”

She saw this same spirit of dedication and drive in CHEST’s leadership and staff, she said — one she will continue and expand upon during her presidency.

“T’ve watched our last three presidents lead by great example ... with innovation and nimbleness, in a time when we were so isolated from each other and so tired from the long hours that we worked each day,” she said. “They, along with the Board of Regents, the CEO, and our phenomenal staff, were able to keep CHEST amazingly alive and vibrant and more connected than ever. They are truly inspiring. For 2023, I hope to take this incredible energy to the next level.”

As CHEST president, Dr. Addrizzo-Harris plans to expand and strengthen the CHEST community by supporting greater cooperation and collaboration with sister societies in the United States and advancing international outreach initiatives launched by CHEST Past President David Schulman, MD, MPH, FCCP. This also includes supporting and building upon CHEST’s ongoing commitment to diversity, equity, and inclusion initiatives to encourage greater representation in the field and improve patient care.

“Whether it’s through supporting our clinical research grants, expanding patient education and advocacy, or programs like the First 5 Minutes™ and the Harold Amos scholarship program, we want to train our leaders for the future,” she said.

Revisit the September issue of CHEST Physician, and watch future issues to learn more about Dr. Addrizzo-Harris and her plans for the presidency.

In memoriam

CHEST has been informed of the following deaths of CHEST members.

We remember our colleagues and extend our sincere condolences.

- Desmond R. Del Giacco, MD, FCCP
- Walter H. Herbert, MD
- Donald C. Zavala, MD
CHEST Challenge returned to the stage in the Music City

BY DANIELLE LEBER
Managing Editor, CHEST News Channels

After several years of virtual competitions, the CHEST Challenge Championship returned to the stage at CHEST 2022 in Nashville, where outstanding fellows from Brooke Army Medical Center, Mayo Clinic, and New York Presbyterian Brooklyn Methodist battled to compete in unconventional skills challenges and clinical trivia.

After an excellent showing from all three institutions, Mayo fellows, Amjad Kanj, MD; Paige Marty, MD; and Zhenmei Zhang, MD, won the day, earning their training program $5,000 (not to mention, the ultimate bragging rights and the chance to raise the coveted Rosen Cup). Runner-up Brooke Army Medical Center received $3,000, and New York Presbyterian Brooklyn Methodist received $1,000.

This year’s Jeopardy-style championship included a variety of category types, including everything from straightforward clinical answers in “Asthmalogic” about asthma-related issues and “Under a Microscope” for topics related to histopathology, to brain-boggling alternate options, such as “Rhyme Time,” which twisted answers in rhyming phrases.

The competition also included timed skills challenges that tested the competitors physically – and presented some very special guests.

In “Bugs and Drugs,” Team Methodist sprinted to grab and then matched unlabeled pathogen photographs with their appropriate therapeutic agents in less than 35 seconds. In another, Team Brooke aced the challenge of performing timed procedures on three different body parts in Dr. Frankenstein’s laboratory, while the monster himself (played by Board of Regents member Victor J. Test, MD, FCCP) worked to distract them.

Mayo Clinic was already in the lead by the time the Final Challenge wager was presented by William Kelly, MD, FCCP, so the team responded to the answer “This disease is inherited as an autosomal recessive trait and is a variant in the SCL34A2 gene” with their own unique reply: “Thank you, CHEST,” and a symbolic wager of $22.

Drs. Kanj, Marty, and Zhang credited their success to their training program back home, as well as the support of friends and colleagues on-site, including Program Director, Darlene Nelson, MD, FCCP. The team also prepared with mock sessions days before the championship and had a strong fan base cheering them on in the audience.

Want to join rising stars in pulmonary, critical care, and sleep medicine for next year’s championship in Hawai‘i? Watch CHEST’s social media in the spring for the first phase of CHEST Challenge.
CHEST 2022 award winners

Each year, CHEST recognizes members who make an impact—through dedication to the organization, by contributions to research and practice, through their commitment to educating the next generation, and so much more.

MASTER FELLOW AWARD
Gerard A. Silvestri, MD, MS, Master FCCP

DISTINGUISHED SERVICE AWARD
Anees A. Das, MD, FCCP

COLLEGE MEDALIST AWARD
William R. Auger, MD, FCCP

ALFRED SOFFER AWARD FOR EDITORIAL EXCELLENCE
Todd W. Rice, MD, FCCP

EARLY CAREER CLINICIAN EDUCATOR AWARD
Mauricio Danckers, MD, FCCP

More award winners

Please Note: Award winners from the following categories will be listed in the February issue of CHEST Physician.

CHEST Foundation Grant Awards
Scientific Abstract Awards
Alfred Soffer Research Award Winners
Young Investigator Award Winners
Abstract Rapid Fire Winners
Case Report Session Winners
Case Report Rapid Fire Winners

CHEST simulation courses support learning for every career stage

One mark of an excellent clinician is their commitment to lifelong learning, and CHEST's hands-on simulation courses offer the chance for practitioners of all experience levels to enhance their knowledge. A variety of interactive courses are offered at CHEST's state-of-the-art Innovation, Simulation, and Training Center in Glenview, Illinois, covering topics like ultrasonography, bronchoscopy, and mechanical ventilation. And this year, our simulation courses— they teach them, too.

Trainees don’t just attend simulation courses—they teach them, too. Carmen Mei, MD, a pulmonary and critical care fellow at Rutgers University, was a faculty member at the recent ultrasound course. She taught attendees representing a wide array of ages.

“It’s a learning environment. Everybody’s very engaged, no matter where they are in their career,” she said.

As a mid-career clinician, Yonatan Y. Greenstein, MD, FCCP—who serves as a co-chair of the ultrasound conference—appreciates the diversity of experiences among attendees.

“Over the years, we’ve found that the wide breadth enhances the course because learners appreciate the questions that are brought up from different angles,” he said.

For experienced clinicians like CHEST Immediate Past President David Schulman, MD, MPH, FCCP, the interactive courses provide an opportunity to continue expanding his expertise. At the ultrasound course, Dr. Schulman said he enjoyed the chance to extend and refine his skillset alongside clinicians with a broad range of experience levels.

“Ultrasound is one of those skills that many clinicians, even in their forties and older, have never trained in. It’s great to see how the more junior learners approach this with a very excited mindset, and they’re learning right beside mid-career faculty who didn’t have the exposure to ultrasound when they were young,” he said.

To find the simulation course that’s the best fit for your practice, visit chestnet.org/simulation.
LUNG CANCER

Screening raises lung cancer survival rate to 80%

BY MARCIA FRELLICK
MDedge News

CHICAGO – Discovering lung cancer early with annual low-dose computed tomography greatly improves long-term survival rates to 80%, findings from a 20-year international study indicate.

Claudia Henschke, MD, PhD, professor of radiology and director of the Early Lung and Cardiac Action Program at the Icahn School of Medicine at Mount Sinai, New York, presented research results at the annual meeting of the Radiological Society of North America.

The researchers studied lung-cancer–specific survival (LCS) of 87,416 participants enrolled in an international, prospective study named the International Early Lung Cancer Action Program.

Lung cancer is the leading cause of cancer death. The American Lung Association states the average 5-year survival rate is 18.6%. Only 16% of the cancers are caught early and more than half of people with lung cancer die within a year of diagnosis.

Participants’ 20-year survival rate 80%
Results of this large international study showed the overall 20-year survival rate for the 1,285 screening participants diagnosed with early-stage cancer was 80% (95% confidence interval, 77%-83%). Among the 1,285 diagnosed, 83% had stage 1 cancer, Dr. Henschke said.

LCS was 100% for the 139 participants with non–solid nodule consistency and for the 155 participants with part-solid consistency. LCS was 73% (95% CI, 69%-77%) for the 991 with solid consistency, and for clinical stage IA participants LCS was 86% (95% CI, 83%-89%), regardless of consistency.

For participants with pathologic stage IA lung cancer 10 mm or less in average diameter, the 20-year survival rate with identification and resection was 92% (95% CI, 87%-96%).

No lung cancer deaths were identified in the part-solid and nonsolid cancers, the researchers report. These results show the 10-year findings from 2006 published in the New England Journal of Medicine (2006 Oct 26. doi: 10.1056/NEJMoA060476), which also showed 80% survival rates with low-dose CT, have persisted, she said.

At the time of the 2006 paper, 95% of Americans diagnosed with lung cancer died from it, Dr. Henschke said.

Dr. Henschke notes that, by the time symptoms appear, lung cancer is often advanced, so the best tool for detecting early-stage lung cancer is enrolling in an annual screening program.

“This bolsters the data that lung cancer screening is beneficial over a longer period of observation,” he said, noting that most of the randomized controlled trials have been shorter.

Lung cancer screening is now recommended for high-risk individuals – those with at least a 20-pack-year history of tobacco use who are between 50 and 80 years old.

So far, screening is still limited to people at high risk, Dr. Hawk said, though there’s discussion about whether benefit would extend to people exposed to asbestos, for instance, or secondhand smoke.

“The biggest challenge right now is getting the screening to those who actually meet the criteria,” Dr. Hawk said.

Medscape reported earlier this month that less than 6% of high-risk smokers have the recommended annual lung cancer screening, according to a new report from the American Lung Association.

Dr. Henschke is on the Advisory Board for LungLifeAI and is on the board for the Early Diagnosis and Treatment Research Foundation. Dr. Hawk reported no conflicts.

Psychological Morbidity After COVID-19 Critical Illness.
By Keerthana Sankar, MD, et al.

Feasibility of a New Lung Ultrasound Protocol to Determine the Extent of Lung Injury in COVID-19 Pneumonia.
By Giovanni Volpicelli, MD FCCP, et al.

“No Escalation of Treatment” Designations: A Multi-institutional Exploratory Qualitative Study.
By Jason N. Batten, MD, et al.
Buzz kill: Lung damage looks worse in pot smokers

BY DONAVYN COFFEY

Scans of the lungs of pot users have turned up an alarming surprise: Regular smokers of marijuana appear to be at greater risk for lung damage than are people who smoke tobacco alone.

“There’s a public perception that marijuana is safe,” said Giselle Revah, MD, a radiologist at the University of Ottawa. “This study is raising concern that this might not be true.”

Dr. Revah said she can often tell immediately if a CT scan is from a heavy or long-time cigarette smoker. But with the legalization and increased use of marijuana in Canada and many U.S. states, she began to wonder what cannabis use does to the lungs and whether she would be able to differentiate its effects from those of cigarette smoking.

She and her colleagues retrospectively examined chest CT scans from 56 marijuana smokers and compared them to scans of 57 non-smokers and 33 users of tobacco alone (Radiology. 2022 Nov 15. doi: 10.1148/radiol.222745). Emphysema was significantly more common among marijuana smokers (75%) than among nonsmokers (5%). When matched for age and sex, 93% of marijuana smokers had emphysema, vs. 67% of those who smoked tobacco only (P = .009).

Without age matching, rates of emphysema remained slightly higher among the marijuana users (75% vs. 67%), although the difference was no longer statistically significant. Yet more than 40% of the marijuana group was younger than 50 years, and all of the tobacco-only users were 50 or older — meaning that marijuana smokers may develop lung damage earlier or with less exposure, Dr. Revah said.

Marijuana smokers also showed higher rates of airway inflammation, including bronchial thickening, bronchiectasis, and mucoid impaction, with and without sex- and age-matching, the researchers found.

The findings are “not even a little surprising,” according to Alan Kaplan, MD, a family physician in Ontario who has expertise in respiratory health. He is the author of a 2021 review on cannabis and lung health (Pulm Ther. 2021 Oct 25. doi: 10.1007/s41030-021-00171-8).

“One reason for the additional damage may be the way marijuana is inhaled,” Dr. Kaplan said.

In an editorial accompanying the journal article by Dr. Revah and colleagues (Radiology. 2022 Nov 15. doi: 10.1148/radiol.222745), pulmonary experts noted that the new data give context to a recent uptick in referrals for nontraumatic pneumothorax.

“Without age matching, rates of lung damage may be the way marijuana is inhaled, Dr. Kaplan said.

Marijuana smokers “take a big breath in, and they really push it into lungs and hold pressure on it, which may actually cause alveoli to distend over time.”

Because most marijuana smokers in the study also smoked cigarettes, whether the observed damage was caused by marijuana alone or occurred through a synergy with tobacco is impossible to discern, Dr. Revah said. Still, the results are striking, she said, because the marijuana group was compared to tobacco users who had an extensive smoking history — 25-100 pack-years — and who were from a high-risk lung cancer screening program.

“The message to physicians is to ask about cannabis smoking,” Dr. Kaplan said. In the past, people have been reluctant to admit to using cannabis. Clinicians should still try to identify frequent users, especially those who are predisposed for lung conditions. If they intend to use the drug, the advice should be, “There are safer ways to use cannabis,” he said.

Dr. Revah and Dr. Kaplan have disclosed no relevant financial relationships.
Persistent asthma linked to increased carotid plaque

By Batya Swift Yasgur, MA, LSW

Persistent asthma is associated with increased carotid plaque burden and higher levels of inflammation, putting these patients at risk for atherosclerotic cardiovascular disease (ASCVD), new research suggests.

Using data from the Multiethnic study of atherosclerosis (MESA), investigators analyzed more than 5,000 individuals, comparing carotid plaque and inflammatory markers in those with and without asthma.

They found that carotid plaque was present in half of participants without asthma and half of those with intermittent asthma but in close to 70% of participants with persistent asthma. Moreover, those with persistent asthma had higher interleukin-6 (IL-6) levels, compared with those without asthma or those with intermittent asthma.

“The take-home message is that the current study, paired with prior studies, highlights that individuals with more significant forms of asthma may be at higher cardiovascular risk and makes it imperative to address modifiable risk factors among patients with asthma,” lead author Matthew Tattersall, DO, MS, of the University of Wisconsin School of Medicine and Public Health, Madison, told this news organization.

The study was published online Nov. 23, 2022 in the Journal of the American Heart Association (doi: 10.1161/JAHA.122.026644).

Asthma and ASCVD are “highly prevalent inflammatory diseases,” the authors write. Carotid artery plaque detected by B-mode ultrasound “represents advanced, typically subclinical atherosclerosis that is a strong independent predictor of incident ASCVD events,” with inflammation playing a “key role” in precipitating these events, they note.

Serum inflammatory markers such as C-reactive protein (CRP) and IL-6 are associated with increased ASCVD events, and in asthma, CRP and other inflammatory biomarkers are elevated and tend to increase during exacerbations. Nevertheless, there are limited data looking at the associations of asthma, asthma severity, and atherosclerotic plaque burden, they note, so the researchers turned to the MESA study – a population of individuals free of prevalent ASCVD at baseline.

They also wanted to explore “whether these associations would be attenuated after adjustment for baseline inflammatory biomarkers.”

Dr. Tattersall said the current study “links our previous work studying the manifestations of asthma,” in which he and his colleagues demonstrated increased cardiovascular events among MESA participants with persistent asthma, as well as late-onset asthma participants in the Wisconsin Sleep Cohort. His group also showed that early arterial injury occurs in adolescents with asthma.

However, there are also few data looking at the association with carotid plaque, “a late manifestation of arterial injury and a strong predictor of future cardiovascular events and asthma,” Dr. Tattersall added. He and his group therefore “wanted to explore the entire spectrum of arterial injury from the initial increase in the carotid media thickness to plaque formation to cardiovascular events.”

To do so, they studied participants in MESA, a study of close to 7,000 adults that began in the year 2000 and continues to follow participants today. At the time of enrollment, all were free from CVD. The analysis looked at 5,029 MESA participants (mean age 61.6 years, 53% female, 26% Black, 23% Hispanic, 12% Asian), compared to those with persistent asthma, defined as “asthma requiring use of controller medications,” intermittent asthma, defined as “asthma without controller medications” and no asthma.

Participants underwent B-mode carotid ultrasound to detect carotid plaques, with a total plaque score (TPS) ranging from 0 to 12.

Participants with persistent asthma were more likely to be women, have higher body mass index (BMI), and higher high-density lipoprotein (HDL) cholesterol levels, than those without asthma.

Participants with persistent asthma had the highest burden of carotid plaque (P = .003 for comparison of proportions and .002 for comparison of means).

Moreover, participants with persistent asthma also had the highest systemic inflammatory marker levels – both CRP and IL-6 – compared with those without asthma. While participants with intermittent asthma also had higher average CRP, compared with those without asthma, their IL-6 levels were comparable.

In unadjusted models, persistent asthma was associated with higher odds of carotid plaque presence (odds ratio, 1.97; 95% confidence interval, 1.32-2.95) – an association that persisted even in models that adjusted for biologic confounders (both P < .01). There also was an association between persistent asthma and higher carotid TPS (P < .001).

In further adjusted models, IL-6 was independently associated with presence of carotid plaque (P = .0001 per 1-SD increment of 1.53), as well as TPS (P < .001). CRP was “slightly associated” with carotid TPS (P = .04) but not carotid plaque presence (P = .07).

There was no attenuation after the researchers evaluated the associations of asthma subtype and carotid plaque presence or TPS and fully adjusted for baseline IL-6 or CRP (P = .02 and P = .01, respectively).

“Our initial hypothesis was that it was driven by inflammation, as both asthma and CVD are inflammatory conditions,” he continued. “We did adjust for inflammatory biomarkers in this analysis, but there was no change in the association.” Nevertheless, Dr. Tattersall and colleagues are “cautious in the interpretation, since the inflammatory biomarkers were only collected at one point, and these measures can be dynamic.”

Robert Brook, MD, professor and director of cardiovascular disease prevention, Wayne State University, Detroit, said the “main contribution of this study is the novel demonstration of a significant association between persistent (but not intermittent) asthma with carotid atherosclerosis in the MESA cohort, a large multi-ethnic population.”

These findings “support the biological plausibility of the growing epidemiological evidence that asthma independently increases the risk for cardiovascular morbidity and mortality,” added Dr. Brook, who was not involved with the study. “The main take-home message for clinicians is that, just like in COPD (which is well-established), asthma is often a systemic condition in that the inflammation and disease process can impact the whole body,” he said.

“Health care providers should have a heightened awareness of the potentially increased cardiovascular risk of their patients with asthma and pay special attention to controlling their heart disease risk factors (for example, hyperlipidemia, hypertension),” Dr. Brook stated.

Dr. Tattersall and co-authors and Dr. Brook declared no financial conflicts.

Inflammatory marker levels by asthma status

<table>
<thead>
<tr>
<th>Marker</th>
<th>No asthma (SD)</th>
<th>Intermittent asthma (SD)</th>
<th>Persistent asthma (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRP (mg/L)</td>
<td>3.61 (5.50)</td>
<td>4.54 (6.80)</td>
<td>6.49 (11.20)</td>
</tr>
<tr>
<td>IL-6 (ng/mL)</td>
<td>1.52 (1.21)</td>
<td>1.60 (1.21)</td>
<td>1.69 (1.61)</td>
</tr>
</tbody>
</table>

Note: The analysis involved 5,029 participants in the Multi-Ethnic Study of Atherosclerosis.

Source: J Am Heart Assoc. 2022 Nov 23:e026644
Designed to help providers quickly and more confidently decipher the risk of malignancy of a lung nodule from a simple blood draw.